FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
SAN DIEGO, May 08, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration. More than a dozen posters were presented at the recent American Association of Cancer Research’s (AACR) 2018 meeting and are now available to watch and download, https://www.crownbio.com/posters/
These scientific posters describe innovations in CrownBio’s Internal R&D focusing on preclinical oncology research. The most compelling work is now available on-demand and narrated by CrownBio scientists. The library of poster presentations includes details on the development and application of several innovative humanized models, a new largescale ex vivo PDX drug screening service and a novel IDO1 inhibition assay platform. Collectively, the data demonstrate CrownBio’s unique capacity to enhance knowledge, guide development decisions and advance immunotherapy programs.
“CrownBio is providing unfettered access to CrownBio’s innovative research with scientific colleagues worldwide,” said Dr. Henry Li, CrownBio’s Vice President of Translational Oncology. “We are committed to sharing with scientists globally the cutting-edge tools that are available to accelerate, inform and enlighten contemporary evaluation of cancer therapies and immunotherapies.”
“Crown Bioscience is committed to making valuable contributions to the scientific community,” said Dr. Jean Pierre Wery, Crown Bioscience’s Chief Executive Officer. “By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs.”
The library of narrated posters can be found on Crown Bioscience’s website, https://www.crownbio.com/posters/
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
